|
|
Visual analysis of research hot spot trends of Buyang Huanwu Decoction in the treatment of angina pectoris of coronary heart disease based on CiteSpace and VOSviewer |
LI Peng1 LU Jinjin2 LI Yuxuan1 ZHANG Yuanyuan1 LI Xingxing1 LIN Qian3 LI Yan2 CUI Xiaoyun2 |
1.The Second Clinical Medical School, Beijing University of Chinese Medicine, Beijing 100029, China;
2.Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China;
3.Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100027, China
|
|
|
Abstract Objective To analyze the relevant study of Buyang Huanwu Decoction in the treatment of angina pectoris of coronary heart disease based on CiteSpace and VOSviewer and to explore the research status and hot trends. Methods The research literatures on the application of Buyang Huanwu Decoction in the treatment of angina pectoris of coronary heart disease collected from CNKI, VIP, WanFang Data, China Biomedical Literature Database, PubMed, and Web of Science from January 1990 to October 2022 were searched by computer. Visualization software CiteSpace 5.5.R2 and VOSviewer 1.6.18 were used to draw the map of scientific knowledge, and the number of publications, authors, institutions, and keywords were analyzed. Results A total of 392 papers were included, and the number of published papers showed a fluctuating upward trend. Research institutions were mainly concentrated in universities and their affiliated hospitals, and high-frequency keywords included “Buyang Huanwu Decoction”, “angina pectoris”, “clinical efficacy”, and so on. There were ten cluster labels and 12 outburst words, respectively. Conclusion The current research focus on clinical research, integrated therapy of traditional Chinese and western medicine, etc., but the discussion of pharmacological mechanism still needs to be further explored. This study provides a reference for the clinical application of Buyang Huanwu Decoction in the treatment of angina pectoris of coronary heart disease angina pectoris.
|
|
|
|
|
[1] Ferrari R,Camici PG,Crea F,et al. Expert consensus document:A ‘diamond’ approach to personalized treatment of ang- ina [J]. Nat Rev Cardiol,2018,15(2):120-132.
[2] 《中国心血管健康与疾病报告2021》编写组.《中国心血管健康与疾病报告2021》要点解读[J].中国心血管杂志,2022,27(4):305-318.
[3] 王天罡,王凤荣.中医药疗法治疗冠心病心绞痛研究概况[J].中国中医急症,2016,25(6):1074-1076.
[4] 牛颖,赵玉洁,王文锋.补阳还五汤化裁治疗冠心病心绞痛(气虚血瘀型)的效果及对患者炎症反应、血管内皮功能的影响[J].临床医学研究与实践,2022,7(13):98-101.
[5] 康焱红,王金星,方芳,等.2012—2022年补阳还五汤研究文献可视化分析[J].中国中医药信息杂志,2023,30(8):50-55.
[6] 陈悦,陈超美,刘则渊,等.CiteSpace知识图谱的方法论功能[J].科学学研究,2015,33(2):242-253.
[7] 吴朦,胡镜清,江丽杰,等.冠心病中医证分类及其关联理化指标的研究[J].世界科学技术-中医药现代化,2016, 18(5):776-785.
[8] 王红彦,李军文,胡才玉,等.中医药治疗冠心病心绞痛的研究现状[J].现代临床医学,2022,48(6):455-457.
[9] 汪强,谷惠敏,朱建中,等.补阳还五汤治疗气虚血瘀型冠心病心绞痛的临床回顾性研究[J].南京中医药大学学报,2017,33(6):579-582.
[10] 周欣欣,李娟,高雅,等.补阳还五汤黄芪不同配比组方调控动脉粥样硬化炎性反应的分子机制研究[J].中华中医药学刊,2022,40(11):171-175,289-291.
[11] 卞敬琦,张玉昆,冯月男,等.补阳还五汤对高脂血症大鼠血液流变学和血小板聚集作用的影响[J].中国医药导报,2021,18(28):40-43,47.
[12] 吴阶平,陈可冀.中国传统医学临床特点及其进展[J].科技导报,1993(4):31-33.
[13] Grundvold I,Skretteberg PT,Liest?覬l K,et al. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men:a 35-year follow-up study [J]. Hypertension,2012,59(2):198-204.
[14] 李苓顼,王敏,刘建勋,等.基于网络药理学与分子对接探讨补阳还五汤治疗冠心病的作用机制[J].中国医药科学,2023,13(3):9-12,25.
[15] 赵璐.补阳还五汤加减治疗冠心病稳定型心绞痛临床研究[J].黑龙江中医药,2022,51(1):75-77.
[16] 郑毅成,鲁卫星,鲁娜.补阳还五汤治疗气虚血瘀型冠心病心绞痛有效性和安全性的Meta分析[J].中西医结合心脑血管病杂志,2021,19(9):1469-1475.
[17] 许楚英.冠心病心绞痛气虚血瘀证应用补阳还五汤的临床研究[J].智慧健康,2022,8(12):109-111.
[18] 牛雯颖,毕悦,张玉昆,等.补阳还五汤适应证研究进展[J].辽宁中医药大学学报,2021,23(8):29-33.
[19] 杨雅钦,张朵,李国秋,等.基于VOSviewer和CiteSpace的半夏泻心汤知识图谱可视化分析[J].中国医药导报,2022,19(9):16-20,36.
[20] 邹烈寰,陈惠.中西医结合治疗不稳定性心绞痛的疗效分析[J].川北医学院学报,2017,32(6):827-830.
[21] 顾振华.中西医结合治疗冠心病心绞痛临床观察[J].实用中医药杂志,2019,35(12):1478-1479.
[22] 雷泽善,曹延玲,张明平,等.中西医结合治疗冠心病心绞痛120例临床观察[J].新中医,2015,47(7):15-17.
[23] 陈永华.中西医结合治疗冠心病心绞痛临床研究[J].中医学报,2014,29(2):269-271.
[24] 薛文静,胡元会,杨一格,等.基于CiteSpace的中医药治疗动脉粥样硬化的文献计量及可视化分析[J].中国医药导报,2022,19(19):16-19,24.
[25] 李兰石,王颖.基于细胞焦亡的中药治疗抑郁症合并冠心病的机制研究进展[J].中国医药导报,2022,19(18):38-41. |
|
|
|